Mizuho analyst Graig Suvannavejh raised the price target on Ideaya Biosciences (NASDAQ: IDYA) to $52.00 (from $46.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Ideaya Biosciences (IDYA) PT Raised to $40 at OppenheimerApril 13, 2026 3:04 PM Ideaya Biosciences (IDYA) PT Raised to $65 at Truist SecuritiesApril 13, 2026 2:05 PM Ideaya Biosciences (IDYA) PT Raised to $35 at Goldman SachsApril 13, 2026 1:29 PM Ideaya Biosciences (IDYA) PT Raised to $58 at WedbushApril 13, 2026 10:14 AM Form 8-K IDEAYA Biosciences, Inc. For: Apr 13April 13, 2026 6:05 AM IDEAYA and Servier report positive phase 2/3 trial results for uveal melanomaApril 13, 2026 6:00 AM IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative MetaApril 13, 2026 6:00 AM IDEAYA to report uveal melanoma trial results April 13April 10, 2026 4:05 PM IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026April 10, 2026 4:05 PM Form 8-K IDEAYA Biosciences, Inc. For: Apr 08April 9, 2026 6:06 AM